Summit Therapeutics INC

Market Movers (8-K)

See all →
NASDAQ
Summit Therapeutics announces the initiation of the global Phase III HARMONi-10 trial for ivonescimab in unresectable Stage III non-small cell lung cancer.
NASDAQ
Summit Therapeutics Inc. has filed a prospectus supplement and related legal opinion regarding its common stock issuance.
Capital raise
NASDAQ
Summit Therapeutics reported strong Q3 2026 results, highlighted by a $2 billion investment from AstraZeneca and positive clinical progress for its lead drug, ivonescimab.
Capital raise
NASDAQ
Summit Therapeutics announces a $2 billion strategic equity investment from AstraZeneca and a clinical trial collaboration to evaluate ivonescimab.
Capital raise
Better than expected
NASDAQ
Summit Therapeutics announced updated overall survival results from its global Phase III HARMONi clinical trial, demonstrating consistent efficacy with ivonescimab plus chemotherapy.
NASDAQ
Updated overall survival data from Akeso's Phase III HARMONi-2 trial for ivonescimab in advanced NSCLC shows a statistically significant benefit compared to pembrolizumab.
Better than expected

Quarterly Earnings (10-Q)

See all →
NASDAQ
Summit Therapeutics reports substantial progress in its ivonescimab development program, highlighted by a significant $2 billion equity investment from AstraZeneca and positive clinical trial updates, alongside a net loss for the period.
Capital raise
NASDAQ
Summit Therapeutics reports on progress in ivonescimab clinical trials and financial performance for Q2 2026, highlighting ongoing development and need for future financing.
Capital raise
NASDAQ
Summit Therapeutics reports Q1 2026 financial results, highlighting ongoing clinical development of ivonescimab and substantial doubt regarding its ability to continue as a going concern.
Capital raise
NASDAQ
Summit Therapeutics reported a significantly wider net loss in Q3 2025, driven by increased R&D and administrative expenses, despite positive clinical trial updates for ivonescimab.
Worse than expected
Delay expected
Capital raise
NASDAQ
Summit Therapeutics reported a significantly increased net loss in Q2 2025, driven by substantial R&D and G&A expenses, despite positive Phase III ivonescimab data and recent capital raises.
Worse than expected
Capital raise
NASDAQ
Summit Therapeutics' Q1 2025 results reflect increased investment in the clinical development of ivonescimab, a novel bispecific antibody for oncology.
Capital raise
Worse than expected

Annual Reports (10-K)

NASDAQ
Summit Therapeutics' Biologics License Application for ivonescimab in EGFR-mutated NSCLC was accepted by the FDA, despite the primary analysis not achieving statistically significant overall survival.
Worse than expected
Capital raise
NASDAQ
Summit Therapeutics Inc. files its 10-K report, detailing financial results for 2024 and outlining progress in the clinical development of its lead candidate, ivonescimab.
Worse than expected
Capital raise
NASDAQ
Summit Therapeutics Inc.'s 10-K filing details its financial position, strategic shift to oncology, and ongoing development of ivonescimab.
Worse than expected
Capital raise

Insider Trading (Form 4)

See all →
NASDAQ
Robert W Duggan, Co-Chief Executive Officer, a Director and 10% owner of Summit Therapeutics Inc., reported multiple transactions in common stock on November 20, 2026.
NASDAQ
Mahkam Zanganeh, Co-Chief Executive Officer, a Director and 10% owner of Summit Therapeutics Inc., reported multiple transactions in common stock on November 20, 2026.
NASDAQ
Robert W Duggan, Co-Chief Executive Officer, a Director and 10% owner of Summit Therapeutics Inc., reported multiple transactions in common stock on November 16, 2026.
NASDAQ
Mahkam Zanganeh, Co-Chief Executive Officer, a Director and 10% owner of Summit Therapeutics Inc., reported multiple transactions in common stock on November 16, 2026.
NASDAQ
Manmeet Singh Soni, COO and CFO and a Director of Summit Therapeutics Inc., reported multiple transactions in common stock on November 16, 2026.
NASDAQ
Bhaskar Anand, Chief Accounting Officer of Summit Therapeutics Inc., received 100,000 shares of common stock on October 8, 2026.

Proxy Statements (Def-14A)

NASDAQ
Summit Therapeutics Inc. is holding a special meeting on November 4, 2026, to seek shareholder approval to increase its authorized common stock by 1 billion shares to facilitate future strategic and financial flexibility.
Capital raise
NASDAQ
Summit Therapeutics Inc. has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, executive compensation, and a stock incentive plan amendment.
Capital raise
NASDAQ
Summit Therapeutics Inc. will hold its 2025 annual meeting of stockholders virtually on June 12, 2025, to vote on the election of directors, ratification of the independent accounting firm, and executive compensation.
NASDAQ
Ujwala Mahatme, a Summit Therapeutics board member since July 2020, has resigned effective June 12, 2024, due to increasing professional commitments, and will not stand for re-election at the upcoming Annual Meeting.
NASDAQ
Summit Therapeutics Inc. has scheduled its 2024 annual meeting of stockholders for June 14, 2024, to be held virtually, and has released its proxy statement outlining proposals for voting.